- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Principal Scientific Adviser to GoI reviews progress to transform India regulatory ecosystem for medical products
![Principal Scientific Adviser to GoI reviews progress to transform India regulatory ecosystem for medical products Principal Scientific Adviser to GoI reviews progress to transform India regulatory ecosystem for medical products](https://medicaldialogues.in/h-upload/2024/08/22/750x450_248987-pib-50-10.webp)
New Delhi: Prof. Ajay Kumar Sood, Principal Scientific Adviser (PSA) to the Government of India took a meeting to review the progress made towards transformation of India's regulatory system. This matter was discussed in the 24th PM-Science Technology Innovation Advisory Council (PM-STIAC) meeting, chaired by the PSA, and held on the 6th of February 2024 on ‘Transforming the regulatory ecosystem of the medical products in India’.
Dr. Rajeev Raghuvanshi, Drug Controller General of India (DCGI), Central Drugs Standard Control Organisation (CDSCO) updated the progress in priority areas identified as part of the PM-STIAC meeting, such as streamlining of the Subject Expert Committee (SEC) review process and internal process improvement with the help of an independent external agency. He also elaborated on the development of an end-to-end digital architecture for the transformation of India’s regulatory ecosystem, consolidation of Review Committee on Genetic Manipulation (RCGM) activities to a single window system thereby reducing the timeline of approvals, developing the scientific capacity of CDSCO, increased digitization, and the recent notification of countries under Rule 101 to simplify access to medical products, among others.
PSA Prof. Sood appreciated the efforts of CDSCO and emphasized that a robust and enabling regulatory ecosystem will help to build trust in domestic and international markets, boost manufacturing and exports. He said that these efforts will further augment the competitive advantage that India has in the manufacturing of medical products and spur innovations in the entire sector.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751